摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

tert-butyl 1-(5-aminopyridin-2-yl)piperidine-4-carboxylate | 892492-27-2

中文名称
——
中文别名
——
英文名称
tert-butyl 1-(5-aminopyridin-2-yl)piperidine-4-carboxylate
英文别名
——
tert-butyl 1-(5-aminopyridin-2-yl)piperidine-4-carboxylate化学式
CAS
892492-27-2
化学式
C15H23N3O2
mdl
——
分子量
277.367
InChiKey
BSRGWRWJTVQBSC-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    450.3±45.0 °C(Predicted)
  • 密度:
    1.134±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2
  • 重原子数:
    20
  • 可旋转键数:
    4
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.6
  • 拓扑面积:
    68.4
  • 氢给体数:
    1
  • 氢受体数:
    5

反应信息

  • 作为反应物:
    描述:
    tert-butyl 1-(5-aminopyridin-2-yl)piperidine-4-carboxylate溶剂黄146 作用下, 以 甲苯 为溶剂, 反应 22.0h, 生成 tert-butyl 1-[5-(2,4-dioxo-1,3-diazinan-1-yl)pyridin-2-yl]piperidine-4-carboxylate
    参考文献:
    名称:
    [EN] BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF
    [FR] AGENTS DE DÉGRADATION BIFONCTIONNELS DE PROGÉNITEUR HÉMATOPOÏÉTIQUE KINASE ET LEURS UTILISATIONS THÉRAPEUTIQUES
    摘要:
    The present disclosure provides bifunctional compounds as HPK1 degraders via ubiquitin proteasome pathway, and method for treating diseases modulated by HPK1.
    公开号:
    WO2023086399A1
  • 作为产物:
    描述:
    tert-butyl 1-(5-nitropyridin-2-yl)piperidine-4-carboxylate 在 铁粉氯化铵 作用下, 以 乙醇 为溶剂, 以72 %的产率得到tert-butyl 1-(5-aminopyridin-2-yl)piperidine-4-carboxylate
    参考文献:
    名称:
    [EN] BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF
    [FR] AGENTS DE DÉGRADATION BIFONCTIONNELS DE PROGÉNITEUR HÉMATOPOÏÉTIQUE KINASE ET LEURS UTILISATIONS THÉRAPEUTIQUES
    摘要:
    The present disclosure provides bifunctional compounds as HPK1 degraders via ubiquitin proteasome pathway, and method for treating diseases modulated by HPK1.
    公开号:
    WO2023086399A1
点击查看最新优质反应信息

文献信息

  • Oxadiazole Derivative as Dgat Inhibitors
    申请人:Birch Martin Alan
    公开号:US20080096874A1
    公开(公告)日:2008-04-24
    Compounds of formula (I), and salts and pro-drugs thereof: Formula (I) wherein for example R 1 is optionally substituted aryl or heteroaryl; Y is a linking group selected from, for example, a direct bond, and a (substituted) alkyl chain; R 2 is an optionally substituted aryl, an optionally substituted cycloalkyl or an optionally substituted heterocyclic group; are described. Processes to make such compounds and their use as DGAT inhibitors, for example in the treatment of obesity, are also described.
    式(I)的化合物,以及其盐和前药:其中,例如R1是可选取代芳基或杂环芳基;Y是选择自直接键和(取代)烷基链等的连接基;R2是可选取代芳基、可选取代环烷基或可选取代杂环基团。还描述了制备此类化合物的方法及其作为DGAT抑制剂的用途,例如在肥胖症的治疗中。
  • OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS
    申请人:BIRCH Alan Martin
    公开号:US20100317653A1
    公开(公告)日:2010-12-16
    Compounds of formula (I), and salts and pro-drugs thereof: wherein for example R 1 is optionally substituted aryl or heteroaryl; Y is a linking group selected from, for example, a direct bond, and a (substituted) alkyl chain; R 2 is an optionally substituted aryl, an optionally substituted cycloalkyl or an optionally substituted heterocyclic group; are described. Processes to make such compounds and their use as DGAT inhibitors, for example in the treatment of obesity, are also described.
    公式(I)的化合物、其盐和前药:其中,例如,R1是可选取代芳基或杂环芳基;Y是选自直接键和(取代)烷基链的连接基;R2是可选取代芳基、可选取代环烷基或可选取代杂环基团。本文描述了制备这种化合物的过程,以及它们作为DGAT抑制剂的用途,例如用于治疗肥胖症。
  • US7795283B2
    申请人:——
    公开号:US7795283B2
    公开(公告)日:2010-09-14
  • [EN] BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF<br/>[FR] AGENTS DE DÉGRADATION BIFONCTIONNELS DE PROGÉNITEUR HÉMATOPOÏÉTIQUE KINASE ET LEURS UTILISATIONS THÉRAPEUTIQUES
    申请人:[en]NURIX THERAPEUTICS, INC.
    公开号:WO2023086399A1
    公开(公告)日:2023-05-19
    The present disclosure provides bifunctional compounds as HPK1 degraders via ubiquitin proteasome pathway, and method for treating diseases modulated by HPK1.
查看更多